All Immuno-oncology articles – Page 3
-
ArticleAI in drug discovery: faster, smarter, better
Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective.
-
ArticleNext-gen ADCs: Tubulis sets new standard in cancer treatment
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
-
NewsNew melanoma therapy prevents brain metastasis in preclinical studies
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
-
WebinarReprogramming immunity: designing smarter checkpoint receptor agonists
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
-
ArticleRefining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
-
NewsAI-designed CDK12/13 inhibitors target resistant cancers
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
-
NewsLeukaemia cells hit hard by innovative dual-drug approach
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
-
ArticleNew therapy shows promise in strengthening CAR-T responses
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
-
NewsNew enzyme discovery could boost cancer immunotherapy
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.
-
NewsCoherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients.
-
ArticleCilta-cel: A new era in multiple myeloma treatment
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
-
NewsNew research shows way to bypass immunotherapy resistance
A study from the University of Alabama at Birmingham reveals that HIF1α plays a crucial role in enabling T cells to kill tumour cells under low-oxygen conditions, providing a potential solution to resistance in immune checkpoint blockade (ICB) therapies.
-
ArticleIn vivo CAR T: Faster, cheaper, and more effective cancer care
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
-
ArticleOvercoming obstacles in personalised medicine
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
-
NewsNew CAR-T therapy shows promise in leukaemia treatment
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
-
NewsMelanoma: predicting immunotherapy-induced side effects
Increased gene activity in the SYK pathway could be the basis of a blood test to identify melanoma patients most susceptible to severe side effects.
-
ArticleBreaking resistance – the future of immunotherapy in oncology
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
-
ArticleThe future of cancer immunotherapy with Elicio Therapeutics
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted ...
-
ReportBeyond the lab: immuno-oncology
Read this in-depth analyses and insights from leading experts in the field focusing on treatments, new technologies and engineered bacteria.
-
ArticleDrug Target Review Immuno-oncology eBook 2023
Download this eBook for FREE. Explore cutting-edge immuno-oncology insights through exclusive interviews and studies by leading experts in the field.
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page